Download Files:
Cabozantinib-d4
SKU
HY-13016S1-Get quote
Category Isotope-Labeled Compounds
Tags Apoptosis;c-Kit;c-Met/HGFR;FLT3;TAM Receptor;VEGFR, Apoptosis;Protein Tyrosine Kinase/RTK, Cancer
Products Details
Product Description
– Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
Web ID
– HY-13016S1
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C28H20D4FN3O5
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398.|[3]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308.|[4]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.
CAS Number
– 1802168-53-1
Molecular Weight
– 505.53
SMILES
– COC(C(OC)=C1)=CC2=C1C(OC(C=C3)=CC=C3NC(C4(CC4)C(NC5=C([2H])C([2H])=C(C([2H])=C5[2H])F)=O)=O)=CC=N2
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;c-Kit;c-Met/HGFR;FLT3;TAM Receptor;VEGFR
Pathway
– Apoptosis;Protein Tyrosine Kinase/RTK
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.